


CRN04894

Cat. No.:	HY-158081
CAS No.:	2392970-97-5
Molecular Formula:	C ₃₃ H ₄₂ F ₃ N ₅ O ₃
Molecular Weight:	613.71
Target:	Melanocortin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CRN04894 (compound 17h) is an orally active MC2R antagonist that demonstrates in vivo efficacy in rat model of adrenocorticotrophic hormone (ACTH)-stimulated corticosterone secretion[1]. CRN04894 binds to human or rat MC2R with K _B values of 0.34 nM and 0.23 nM, respectively[1].									
IC₅₀ & Target	rat MC2R 0.23 nM (Kb)	MC2R 0.34 nM (Kb)								
In Vivo	<p>CRN04894 (compound 17h) (3, 30 mg/kg; po; single dose) dose-dependently reduces corticosterone secretion levels in an ACTH-stimulated male rat model[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Adrenocorticotrophic hormone (ACTH)-stimulated corticosterone secretion in Male Sprague-Dawley Rats[1]</td> </tr> <tr> <td>Dosage:</td> <td>3 mg/kg, 30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>po; single dose; ACTH(1-24) stimulated at 4 hr after CRN04894 treatment.</td> </tr> <tr> <td>Result:</td> <td>Significantly decreased the concentration level of corticosterone via oral administration.br/</td> </tr> </table>		Animal Model:	Adrenocorticotrophic hormone (ACTH)-stimulated corticosterone secretion in Male Sprague-Dawley Rats[1]	Dosage:	3 mg/kg, 30 mg/kg	Administration:	po; single dose; ACTH(1-24) stimulated at 4 hr after CRN04894 treatment.	Result:	Significantly decreased the concentration level of corticosterone via oral administration.br/
Animal Model:	Adrenocorticotrophic hormone (ACTH)-stimulated corticosterone secretion in Male Sprague-Dawley Rats[1]									
Dosage:	3 mg/kg, 30 mg/kg									
Administration:	po; single dose; ACTH(1-24) stimulated at 4 hr after CRN04894 treatment.									
Result:	Significantly decreased the concentration level of corticosterone via oral administration.br/									

REFERENCES

[1]. Kim SH, et al. Discovery of CRN04894: A Novel Potent Selective MC2R Antagonist. ACS Med Chem Lett. 2024 Mar 19;15(4):478-485.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA